The 2023 Annual Spring Meeting of the ABA Antitrust Law Section offered the Our Curious […]
There is a lot going on in the European competition law world and the European […]
Illumina’s acquisition of GRAIL is the first deal caught by the European Commission’s reinterpretation of […]
A difficult merger control or antitrust case requires good external communications alongside the legal and […]
Generics and biosimilars are an important part of the pharmaceutical landscape in Europe. What are […]
Standard Essential Patent (SEP) licensing and valuation is an extremely challenging and difficult area worldwide. […]
The European Commission’s EU State aid investigations into the tax ruling practices of EU countries […]
Climate change is one of the most pressing issues facing the world and responses are […]
The pricing of pharmaceuticals, and in particular whether prices are “too high” or “excessive”, is […]
A discussion of the increasing impact of Chinese companies on the EU and worldwide and […]